Overview

Infliximab and Adalimumab in Irritable Bowel Disease Patients.

Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This study aims to assess trough, TREM-1 levels and efficacy of IFX and ADA in IBD patients.
Phase:
N/A
Details
Lead Sponsor:
Rehab Werida
Treatments:
Adalimumab
Infliximab